Clinical Trials Browser

Phase 2 × Glioblastoma × Imatinib Mesylate × Clear all

NCT00171938 2017-02-24

Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)

Phase 2 Terminated

Brain Neoplasms, Glioblastoma

NCT00615927 2013-03-15

Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)

Phase 2 Completed

64 enrolled 9 charts

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00354913 2013-01-18

Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma

Phase 2 Completed

21 enrolled 8 charts

Brain Neoplasms, Glioblastoma, Meningioma, Gliosarcoma

NCT00039364 2012-07-24

Imatinib Mesylate in Treating Patients With Gliomas

Phase 2 Completed

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Glioma, Subependymal, Gliosarcoma

NCT00290771 2011-05-16

Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)

Phase 2 Terminated

231 enrolled 12 charts

Glioblastoma, Glioma